March 28, 2014
The Sixth Circuit on Friday affirmed a lower court's rejection of a shareholder class action against BioMimetic Therapeutics Inc., finding that the company may have believed what it was saying when it told investors its bone- and tissue-regenerating product would be approved by the U.S. Food and Drug Administration.